Rt-PA in the Treatment of Acute Ischemic Stroke
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.
Drug: rt-PA 0.9 mg/kg verum or placebo Intravenous
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Placebo Controlled Trial of Alteplase in Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.30 Hours After Stroke Onset.|
Show 142 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|